Partnerships

N2COx is a founding member of the GIP “Centre Régional de Nutrition Humaine Grand-Ouest” (CRNH) with leadership in the topic “Lipids in chronic pathologies”.
N2Cox have also played a crucial role in structuring the CGO by coordinating 3 networks: “3MC: Molécules marines, métabolisme et Cancer” (C Vandier), “NET: Niches et Epigénétique des Tumeurs” (O Herault) and “CasTHor: Cancers des Tissus Hormono-dépendants” (G Fromont). Moreover, G Fromont coordinates the CGO “Réseau des tumorothèques”.

N2COx members are part of 3 regional networks, Biotechnocentre, “Molecular and technological innovation for Health” (MotivHealth) and ” Institut Européen d'Histoire et des Cultures de l'Alimentation ” (IEHCA).

N2COx is a founding member of NACRe and MeetOchondrie networks.

N2COx is also a founding member of the CNRS GDR 2082 APPICOM “Integrative approaches for the study of membrane proteins”, that gathers 91 research teams from 49 research institutes, in France and abroad.

N2Cox is a founding member of OPALE Carnot Institute.

In addition, N2COx are members of the LabEx Mabimprove, focused on therapeutic antibodies.

International collaborations have been developed with associated publications, patents, PhD co-directions (Mexico, Ireland, Canada, USA, Tunisia, Spain, Lebanon and England) and we are the host laboratory for students from Birmingham medical school (UK), University of Padua (Italy), University of Beirut (Lebanon).

In addition, with LE STUDIUM Loire Valley Institute for Advanced Studies, we have recruited researchers and organized international meeting.

A European company issued from the team has been created in 2021, named Lifesome Therapeutics. It is composed of 3 co-founders including C Vandier. The purpose of this company, positioned in the field of nanotechnology, is the development of a nano vector. It will ensure the valorization of research to which C Vandier participated within N2COx, related to the development of anti-metastatic agents targeting the SK3 channel. This work has led to the family of patents entitled "Method for preventing cancer metastasis", for which the priority application was filed on February 18, 2010 (EP2536414), co-owned by Tours University, INSERM, and Western Brittany University.